Targeting SRC and Stat3 Signaling in EGFR-Driven Non-Small Cell Lung Cancer
Dr. Haura’s hypothesis is that the tyrosine kinase SRC and the protein Stat3 are ideal targets for cancer therapy in lifelong non-smokers who develop lung cancer resulting from EGFR mutations. He is conducting experiments to demonstrate that inhibitors of SRC and/or Stat3 can kill cancer cells. Such inhibitors may have additive effect when used in connection with EGFR inhibitors such as gefitinib or erlotinib.